Literature DB >> 9152248

Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors.

R S Apte1, E Mayhew, J Y Niederkorn.   

Abstract

PURPOSE: To study the effect of aqueous humor (AH)-mediated inhibition of natural killer (NK) cell activity on intraocular tumor progression.
METHODS: Two NK-sensitive tumors, RMA-S lymphoma and OCM-3 uveal melanoma, were tested in vitro for susceptibility to NK cell-mediated lysis in the presence or absence of AH in conventional cytotoxicity assays. Various numbers of RMA-S and OCM-3 tumor cells were injected either subcutaneously or intracamerally into C57BL/6 severe combined immunodeficiency mice and BALB/c nude mice respectively and tumor growth was monitored. The role of NK cell-mediated cytotoxicity in controlling tumor growth was confirmed by depleting NK cells in severe combined immunodeficiency mice by administering anti-asialo GM1 antibodies before subcutaneous tumor injection.
RESULTS: AH significantly inhibited NK cell-mediated lysis of RMA-S and OCM-3 tumor cells in vitro and in vivo. NK sensitive RMA-S (1 x 10(4) cells) and OCM-3 tumors (1 x 10(6), 5 x 10(6) cells) were rejected after subcutaneous injection in C57BL/6 mice, whereas the same or even lower numbers of cells grew progressively in the eye. In vivo NK cell depletion resulted in progressive growth of subcutaneously injected RMA-S tumors at a dose rejected by mice with normal NK cell activity.
CONCLUSIONS: AH inhibits NK cell activity in vitro and within the interior of the eye and prevents the rejection of NK-sensitive intraocular tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152248

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  14 in total

Review 1.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 2.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

Review 3.  Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.

Authors:  Kimberly M Komatsubara; Richard D Carvajal
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

Review 4.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 5.  Immune privilege of corneal allografts.

Authors:  Jerry Y Niederkorn; D Frank P Larkin
Journal:  Ocul Immunol Inflamm       Date:  2010-06       Impact factor: 3.070

6.  Cornea: Window to Ocular Immunology.

Authors:  Jerry Y Niederkorn
Journal:  Curr Immunol Rev       Date:  2011-08

7.  Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.

Authors:  Peter W Chen; Jessamee K Mellon; Elizabeth Mayhew; Shixuan Wang; Yu Guang He; Nick Hogan; Jerry Y Niederkorn
Journal:  Exp Eye Res       Date:  2007-07-25       Impact factor: 3.467

Review 8.  Corneal transplantation and immune privilege.

Authors:  Jerry Y Niederkorn
Journal:  Int Rev Immunol       Date:  2013-02       Impact factor: 5.311

Review 9.  What causes alopecia areata?

Authors:  K J McElwee; A Gilhar; D J Tobin; Y Ramot; J P Sundberg; M Nakamura; M Bertolini; S Inui; Y Tokura; L E King; B Duque-Estrada; A Tosti; A Keren; S Itami; Y Shoenfeld; A Zlotogorski; R Paus
Journal:  Exp Dermatol       Date:  2013-09       Impact factor: 3.960

10.  Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism?

Authors:  Jerry Y Niederkorn
Journal:  Front Immunol       Date:  2012-06-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.